A carregar cotações...
Previsão
Não temos dados de analistas para esta empresa.
Notícias Ir para o feed de notícias
BACHEM: Chief Commercial Officer Torsten Wöhr leaves the company
BACHEM confirms the departure of Chief Commercial Officer Torsten Wöhr. No further details on the timing of his exit or on his successor were given in the announcement. » Mais em finanzen.net
BACHEM pays CHF 0.90 dividend for 2025
At its general meeting, BACHEM approved a dividend of CHF 0.90 per share for 2025, an increase of 5.88% from the previous year. A total of CHF 30.73 million will be distributed, but the total payout is nevertheless 48.77% below last year’s level. The dividend yield for 2025 is 1.50%; the share price rose 35.15% over one year (total return including dividend: 38.13%). FactSet analysts expect a dividend of CHF 1.01 for 2026 (expected yield 1.48%). » Mais em finanzen.net
BACHEM: 100‑franc investment five years ago would be 2.92% down today
If 100 CHF had been invested in BACHEM stock five years ago (closing price then 72.00 CHF), investors would now hold 1.389 shares worth 97.08 CHF (closing price 23 Jan 2026: 69.90 CHF). That corresponds to a loss of 2.92%. BACHEM most recently reported a market capitalization of 5.23 billion CHF; stock splits and dividends were not considered in the calculation. » Mais em finanzen.net
Dividendos históricos Dividendos
Todos os indicadores de dividendos Todos os indicadoresDados financeiros da empresa
| (EUR) | junho de 2026 | |
|---|---|---|
| Receitas | 353,66 mi | - |
| Ganho bruto | 88,46 mi | - |
| Ganho líquido | 54,46 mi | - |
| EBITDA | 89,12 mi | - |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 6,1 bi |
Número de ações | 74,94 mi |
Máximo/mínimo de 52 semanas | € 88,07 - € 51,33 |
Rentabilidade de dividendos | 1,21% |
Dividendos TTM | € 0,98 |
Beta | 0,80 |
PER (PE Ratio) | 38,67 |
PEG (PEG Ratio) | 3,46 |
P/VC (PB Ratio) | 3,99 |
P/V (PS Ratio) | 8,14 |
Perfil da empresa
Die Bachem Holding AG liefert Produkte für die Forschung, die klinische Entwicklung und die kommerzielle Anwendung an Pharma- und Biotechnologieunternehmen weltweit. Das Unternehmen befasst sich mit der Entwicklung, Produktion und regulatorischen Unterstützung von peptidischen pharmazeutischen Wirkstoffen, wie Peptid- und Oligonukleotid-NCEs (New Chemical Entities). Darüber hinaus bietet es kommerzielle NCEs und Generika sowie Dienstleistungen in den Bereichen Projektmanagement, Qualität und Regulierung, Analytik, Produktion nach guter Herstellungspraxis, Produktion in Forschungsqualität sowie Lieferung und vertikale Integration an. Das Unternehmen wurde 1971 gegründet und hat seinen Hauptsitz in Bubendorf, Schweiz. Die Bachem Holding AG ist eine Tochtergesellschaft der Ingro Finanz AG.
| Nome | Bachem Holding AG |
| CEO | Anne-Kathrin Stoller |
| Sede | Bubendorf,
bl Suíça |
| Site | |
| Setor | Cuidados de saúde |
| Indústria | Cuidados de saúde: prestadores e serviços |
| Entrada em bolsa | 16/07/2012 |
| Colaboradores | 2.725 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
London Stock Exchange | 0QND.L |
SIX | BANB.SW |
Pnk | BCHMF |
London | 0QND.L |
